📢 Ask Dr. Bikman’s Digital Mind (multilingual):

https://benbikman.com/ben-bikmans-digital-ai-mind

📢 Dr. Bikman’s Community & Coaching Site: https://insuliniq.com

Note:

Our friends at SiBio CKM are offering a 5% discount using the code BEN5 at checkout. However, their CKM is not yet available in the United States and Canada. It is currently available in selected countries including the UK, Australia, Ireland, the Netherlands, and Germany. You can view the full list of supported countries on their website. Also, you can submit your email on their website and they will notify you when it becomes available in your region: https://www.sibiosensor.com/BEN5

Summary:

Ben explains the four major ways to measure ketones: urine strips, breath analyzers, finger-prick blood meters, and the newer continuous ketone monitor. He begins by reviewing the three ketone bodies produced during fat-based metabolism: acetoacetate, beta-hydroxybutyrate (BHB), and acetone. Each testing method measures a different ketone molecule, which explains why results often do not match across devices.

Urine strips measure acetoacetate, making them inexpensive and useful early in a ketogenic diet, but they become less reliable as the body adapts and uses ketones more efficiently. Breath analyzers measure acetone, offering a reusable and non-invasive option, but they are vulnerable to breathing technique, alcohol, environmental compounds, and imperfect correlation with blood BHB. Blood meters measure BHB directly and remain the practical gold standard for spot-checking nutritional ketosis, but they require finger pricks and costly strips.

The newest tool is the continuous ketone monitor, which measures BHB in interstitial fluid and provides hundreds of readings per day. Dr. Bikman explains that this makes it possible to see trends, overnight patterns, meal responses, supplement effects, and individual variability in a way that spot-check methods cannot capture. The practical takeaway is that continuous ketone monitoring changes the question from “What are my ketones right now?” to “How does my body respond over time?”

References:

For complete show notes and references, we invite you to become an Insider subscriber. You’ll enjoy real-time, livestream Metabolic Classroom access which includes live Q&A with Ben after the lecture, unlimited access to Dr. Bikman’s Digital Mind, ad-free podcast episodes, show notes and references, and Ben’s Weekly Research Review Podcast. Learn more: https://www.benbikman.com

NOTE: The information presented is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Dr. Bikman is not a clinician—and, he is not your doctor. Always seek the advice of your own qualified health providers with questions you may have regarding medical conditions.

#Ketones #KetoneTesting #ContinuousKetoneMonitor #CKM #BetaHydroxybutyrate #BHB #Ketosis #MetabolicHealth #KetoScience #LowCarbScience #FatAdaptation #UrineKetones #BreathKetones #BloodKetones #MetabolicFlexibility #HealthTracking #DrBenBikman #MetabolicClassroom #KetogenicDiet #MetabolismMatters

Ben’s favorite yerba mate and fiber: https://ufeelgreat.com/usa/en/c/1BA884

Exogenous ketones: A high-quality option is the NSF-certified goBHB from Clean Form Nutrition, where you can use the code BEN10 for a 10% discount: https://cleanformnutrition.com/products/go-bhb

Ben’s favorite meal-replacement shake: https://gethlth.com (discount: BEN10)

Hosted on Acast. See acast.com/privacy for more information.

📢 Ask Dr. Bikman’s Digital Mind (multilingual): https://benbikman.com/ben-bikmans-digital-ai-mind

📢 Dr. Bikman’s Community & Coaching Site: https://insuliniq.com

Topic:

Retatrutide activates GLP-1, GIP, and glucagon receptors, combining appetite suppression with increased energy expenditure and powerful liver fat reduction. Dr. Bikman argues that its best use is not as a permanent shortcut, but as a tool to help people regain control over food habits and eventually reduce reliance on medication.

Summary:

Dr. Ben Bikman explains retatrutide, a next-generation metabolic drug that activates three receptors at once: GLP-1, GIP, and glucagon. While semaglutide targets GLP-1 and tirzepatide targets GLP-1 plus GIP, retatrutide adds a third arm through glucagon receptor activation. This makes it distinct because GLP-1 and GIP mainly reduce food intake, while glucagon adds an energy-output effect by increasing fat oxidation, liver fat clearance, and energy expenditure.

Dr. Bikman focuses especially on glucagon because it is the novel feature of retatrutide. In the liver, glucagon stimulates fat burning, suppresses new fat production, promotes hepatic fat clearance, and increases energy expenditure through futile cycling and FGF21 signaling. Human trials show remarkable reductions in body weight and liver fat, with some studies reporting over 80% relative reductions in hepatic fat content and nearly 90% of treated participants reaching normal liver fat levels.

He also explains that glucagon receptors are not expressed on skeletal muscle, which means the drug’s glucagon arm should not directly signal muscle breakdown. Instead, the liver and fat tissue respond while muscle largely ignores the glucagon signal. The practical takeaway is that retatrutide may represent the next major step in incretin-based therapy, but Dr. Bikman emphasizes again that these drugs should ideally be used as a temporary tool—a crutch—to help people reduce cravings, relearn eating patterns, and ultimately rely less on medication over time.

References:

For complete show notes and references, we invite you to become an Insider subscriber. You’ll enjoy real-time, livestream Metabolic Classroom access which includes live Q&A with Ben after the lecture, unlimited access to Dr. Bikman’s Digital Mind, ad-free podcast episodes, show notes and references, and Ben’s Weekly Research Review Podcast. Learn more: https://www.benbikman.com

NOTE: The information presented is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Dr. Bikman is not a clinician—and, he is not your doctor. Always seek the advice of your own qualified health providers with questions you may have regarding medical conditions.

Hosted on Acast. See acast.com/privacy for more information.

📢 Ask Dr. Bikman’s Digital Mind (multilingual):

https://benbikman.com/ben-bikmans-digital-ai-mind

📢 Dr. Bikman’s Community & Coaching Site: https://insuliniq.com

Topic:

Tirzepatide activates both GLP-1 and GIP receptors, producing weight loss primarily through appetite suppression, slower gastric emptying, reduced cravings, and improved insulin sensitivity—not by forcing the pancreas to make more insulin. Dr. Bikman argues that its best use may be as a temporary tool to help people regain control of food choices and lower the insulin-driving habits that caused metabolic dysfunction.

Summary:

In this mini-lecture, Dr. Bikman explains tirzepatide, the dual-incretin drug that activates both GLP-1 and GIP receptors. While it is often described as a drug that improves glucose by increasing insulin, Dr. Bikman argues that this explanation misses the bigger metabolic picture.

He begins by reviewing the incretin effect, where oral glucose produces a stronger insulin response than the same glucose given intravenously because the gut releases hormones such as GLP-1 and GIP. GLP-1 reduces appetite, slows gastric emptying, suppresses glucagon, and helps regulate glucose, while GIP has traditionally been viewed as more fat-storing because of its actions on fat cells.

Ben then resolves the “GIP paradox”: blocking GIP can cause weight loss in animals, yet activating GIP through tirzepatide also causes weight loss. The key, he argues, is insulin. GIP can amplify fat storage only when insulin is elevated, but tirzepatide lowers fasting insulin, reduces meal-related insulin demand, and reduces cravings for foods that drive insulin high. In that lower-insulin context, GIP may support healthier fat tissue function, improve adiponectin, reduce adipose hypoxia, and allow higher GLP-1 activity with better tolerability.

The practical takeaway is that tirzepatide should not be viewed as a magic weight-loss injection or a permanent substitute for lifestyle change. Used wisely, it may serve as a temporary tool to reduce carbohydrate cravings, improve satiety, lower insulin demand, and help people relearn healthier eating patterns.

References:

For complete show notes and references, we invite you to become an Insider subscriber. You’ll enjoy real-time, livestream Metabolic Classroom access which includes live Q&A with Ben after the lecture, unlimited access to Dr. Bikman’s Digital Mind, ad-free podcast episodes, show notes and references, and Ben’s Weekly Research Review Podcast. Learn more: https://www.benbikman.com

NOTE: The information presented is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Dr. Bikman is not a clinician—and, he is not your doctor. Always seek the advice of your own qualified health providers with questions you may have regarding medical conditions.

Hosted on Acast. See acast.com/privacy for more information.